Compounds > 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Page last updated: 2024-09-03

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Ovarian Neoplasms

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Ovarian Neoplasms in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.88)18.2507
2000's6 (35.29)29.6817
2010's8 (47.06)24.3611
2020's2 (11.76)2.80

Authors

AuthorsStudies
Feng, Z; Ge, H; Ju, X; Liu, S; Song, S; Wu, X; Xu, X1
Chea, J; Colcher, D; Li, L; Liu, A; Miller, AD; Minnix, M; Poku, E; Rockne, RC; Shively, JE; Wong, JYC; Yazaki, PJ1
Altai, M; Andersson, K; Boerman, O; Eek, A; Orlova, A; Varasteh, Z1
Abrahmsen, L; Ekblad, C; Frejd, FY; Jonsson, A; Lindborg, M; Lundqvist, H; Orlova, A; Rosik, D; Tolmachev, V1
Dennler, P; Grünberg, J; Jeger, S; Mier, W; Sarko, D; Schibli, R; Zimmermann, K1
Eriksson Karlström, A; Honarvar, H; Orlova, A; Perols, A; Selvaraju, RK; Strand, J; Tolmachev, V1
Cai, W; Cao, F; Chen, K; Chen, X; Lee, A; Li, Z; Liu, Z; Wang, H; Wu, JC1
Bao, A; Cheng, Z; Hoppmann, S; Liu, H; Liu, S; Miao, Z; Ren, G1
Baastrup, B; Feldwisch, J; Lindborg, M; Orlova, A; Sandström, M; Tolmachev, V1
Cheng, Z; Gambhir, SS; Liu, H; Liu, Z; Miao, Z; Ren, G; Syud, FA; Webster, JM; Zhang, R1
Abbas, N; Brevik, EM; Dahle, J; Heyerdahl, H; Mollatt, C1
Grünberg, J; Knogler, K; Novak-Hofer, I; Schubiger, PA; Zimmermann, K1
Boerman, OC; Corstens, FH; Dijkgraaf, I; Frielink, C; Kruijtzer, JA; Liskamp, RM; Oyen, WJ1
Bruchertseifer, F; Huber, T; Kessler, H; Knör, S; Magdolen, V; Morgenstern, A; Sato, S; Schmitt, M; Seidl, C; Senekowitsch-Schmidtke, R1
Cao, W; Carrasquillo, J; Konner, JA; Larson, SM; O'Donoghue, J; Old, LJ; Pandit-Taskar, N; Philips, MD; Smith-Jones, PM1
Amano, R; Kawai, K; Mori, H; Ogawa, K; Shikano, N; Washiyama, K; Yoshimoto, M1
Courtenay-Luck, NS; Epenetos, AA; Gooden, CS; Kosmas, C; McCall, MJ; Meares, CF; Snook, D1

Trials

1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Ovarian Neoplasms

ArticleYear
Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Cancer research, 1992, Feb-15, Volume: 52, Issue:4

    Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibody Formation; Breast; Breast Neoplasms; Chelating Agents; Drug Evaluation; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Radioimmunotherapy; Radionuclide Imaging; Stomach Neoplasms; Testicular Neoplasms; Yttrium Radioisotopes

1992

Other Studies

16 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Ovarian Neoplasms

ArticleYear
Head-to-head comparison of [
    European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:5

    Topics: Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines

2023
TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021, Volume: 62, Issue:1

    Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Mice; Molecular Targeted Therapy; Ovarian Neoplasms; Radioimmunotherapy; Tissue Distribution

2021
In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
    Cancer biotherapy & radiopharmaceuticals, 2013, Volume: 28, Issue:3

    Topics: Animals; Cell Line, Tumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Indium Radioisotopes; Kidney; Male; Mice; Molecular Imaging; Opossums; Ovarian Neoplasms; Radiopharmaceuticals; Receptor, ErbB-2; Recombinant Fusion Proteins; Technetium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2013
Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

    Topics: Albumins; Animals; Binding Sites; Cell Line, Tumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Mice; Ovarian Neoplasms; Protein Structure, Tertiary; Protein Transport; Radioisotopes; Radiometry; Receptor, ErbB-2; Recombinant Fusion Proteins; Substrate Specificity; Tissue Distribution

2013
DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Chelating Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunoglobulin G; Immunoglobulin Heavy Chains; Mice; Ovarian Neoplasms; Polylysine; Radiopharmaceuticals; Tissue Distribution; Transglutaminases; Transplantation, Heterologous

2013
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.
    Molecular imaging, 2014, Volume: 13

    Topics: Animals; Cell Line, Tumor; Chelating Agents; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isotope Labeling; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Positron-Emission Tomography; Recombinant Fusion Proteins

2014
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation.
    Cancer research, 2009, Apr-01, Volume: 69, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Copper Radioisotopes; Embryonic Stem Cells; Endothelial Cells; Female; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Mice; Mice, Nude; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Teratoma; Transplantation, Heterologous

2009
Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Bioconjugate chemistry, 2011, Mar-16, Volume: 22, Issue:3

    Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Models, Molecular; Molecular Weight; Ovarian Neoplasms; Positron-Emission Tomography; Protein Conformation; Protein Transport; Radiochemistry; Radiometry; Receptor, ErbB-2; Recombinant Fusion Proteins; Serum Albumin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2011
Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:5

    Topics: Amino Acid Sequence; Aminocaproic Acid; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isotope Labeling; Mice; Molecular Sequence Data; Ovarian Neoplasms; Peptides; Radionuclide Imaging; Recombinant Fusion Proteins

2011
In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
    Amino acids, 2012, Volume: 43, Issue:1

    Topics: Animals; Binding Sites; Breast Neoplasms; Copper Radioisotopes; Female; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Mice; Mice, Nude; Molecular Mimicry; Neoplasm Transplantation; Ovarian Neoplasms; Positron-Emission Tomography; Protein Binding; Proteins; Receptor, ErbB-2; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous

2012
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Animals; Antibodies, Monoclonal, Humanized; Autoradiography; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Mice; Mice, Nude; Organometallic Compounds; Ovarian Neoplasms; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays

2012
Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Nuclear medicine and biology, 2006, Volume: 33, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Cell Line; Chelating Agents; Drug Evaluation, Preclinical; Female; Glycosylation; Heterocyclic Compounds, 1-Ring; Humans; Liver; Lutetium; Metabolic Clearance Rate; Mice; Mice, Nude; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Radioisotopes; Radiopharmaceuticals

2006
Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    International journal of cancer, 2007, Feb-01, Volume: 120, Issue:3

    Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Injections, Intraperitoneal; Injections, Intravenous; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Peritoneal Neoplasms; Radiopharmaceuticals; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays

2007
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:1

    Topics: Alpha Particles; Animals; Bismuth; Cell Line, Tumor; Dimerization; Drug Discovery; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Ligands; Mice; Neoplasm Metastasis; Ovarian Neoplasms; Peptides; Polygeline; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Solubility; Substrate Specificity; Tissue Distribution

2008
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
    Nuclear medicine and biology, 2008, Volume: 35, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Transport, Active; Carrier Proteins; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Folate Receptors, GPI-Anchored; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Indium Radioisotopes; Iodine Radioisotopes; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pilot Projects; Radiography; Radioimmunodetection; Radiopharmaceuticals; Receptors, Cell Surface; Tissue Distribution

2008
alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    International journal of cancer, 2008, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Integrin alphaVbeta3; Isotope Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Protein Conformation; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2008